Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors
- PMID: 16540932
- DOI: 10.1097/01.qai.0000197071.77482.6e
Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors
Abstract
Background: Adherence to antiretroviral medications is critical to achieving HIV viral suppression. Studies have been limited to cross-sectional analyses using measures that reflect only the percentage of prescribed doses taken (percent adherence), however. The contribution of dose timing and other factors to achieving virologic suppression has received less scrutiny.
Methods: In a longitudinal study, we collected detailed adherence information using multiple tools along with demographic, clinical, social-behavioral, and virologic measures. Subjects were followed for 48 weeks. Percent adherence, dose-timing, genotypic sensitivity, and virologic outcomes were collected every 4 weeks. Repeated measures mixed effects models (RMMEMs) were used to model the relation between virologic outcomes and adherence as well as genotypic sensitivity and others.
Results: Of the 141 subjects, mean percent adherence was 73% with a downward trend. Viral load (VL) dropped significantly (P = 0.01) over time. RMMEMs revealed that higher genotypic sensitivity, higher percent adherence, lower baseline VL, longer inclusion in the study, earlier HIV stage, and smaller dose-timing error were significantly associated with lower VL. In multivariate modeling, a 0.50 increase in the genotypic sensitivity score, a 10% increase in adherence, and a decrease of 3 hours of dose-timing error were associated with a decrease in log10 HIV RNA at 48 weeks of 0.69, 0.54, and 0.48, respectively (P < 0.05 for each).
Conclusions: Long-term viral suppression requires consistent and high percent adherence accompanied by optimal interdose intervals. Efforts to improve viral outcomes should address not only missed doses but excessive variation in dose timing and prevention of adherence decline over time. Preventing the development and transmission of resistant variants is also critically important.
Similar articles
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.AIDS. 2007 May 11;21(8):965-71. doi: 10.1097/QAD.0b013e32802e6bfa. AIDS. 2007. PMID: 17457090 Clinical Trial.
-
Repeated measures analyses of dose timing of antiretroviral medication and its relationship to HIV virologic outcomes.Stat Med. 2007 Feb 28;26(5):991-1007. doi: 10.1002/sim.2592. Stat Med. 2007. PMID: 16755546
-
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. doi: 10.1097/00126334-200212150-00002. J Acquir Immune Defic Syndr. 2002. PMID: 12473833 Clinical Trial.
-
A meta-analysis of adherence to antiretroviral therapy and virologic responses in HIV-infected children, adolescents, and young adults.AIDS Behav. 2013 Jan;17(1):41-60. doi: 10.1007/s10461-012-0159-4. AIDS Behav. 2013. PMID: 22411426 Review.
Cited by
-
Implementation challenges for long-acting antivirals as treatment.Curr Opin HIV AIDS. 2015 Jul;10(4):282-9. doi: 10.1097/COH.0000000000000158. Curr Opin HIV AIDS. 2015. PMID: 26049955 Free PMC article. Review.
-
Substance abuse and medication adherence among HIV-positive women with histories of child sexual abuse.AIDS Behav. 2006 May;10(3):279-86. doi: 10.1007/s10461-005-9041-y. AIDS Behav. 2006. PMID: 16501869 Free PMC article.
-
A Behavioral Adherence Intervention Improves Rates of Viral Suppression Among Adherence-Challenged People Living with HIV in South India.AIDS Behav. 2020 Jul;24(7):2195-2205. doi: 10.1007/s10461-020-02785-6. AIDS Behav. 2020. PMID: 31933020 Free PMC article.
-
Depression at antiretroviral therapy initiation and clinical outcomes among a cohort of Tanzanian women living with HIV.AIDS. 2017 Jan 14;31(2):263-271. doi: 10.1097/QAD.0000000000001323. AIDS. 2017. PMID: 27835614 Free PMC article.
-
Cognitive behavioral therapy for body image and self-care (CBT-BISC) in sexual minority men living with HIV: A randomized controlled trial.Health Psychol. 2017 Oct;36(10):937-946. doi: 10.1037/hea0000505. Epub 2017 May 25. Health Psychol. 2017. PMID: 28541068 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical